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Abstract
Background: Despite its first discovery by in silico cloning of novel endothelial cell-specific genes a decade ago, the
biological functions of endothelial cell-specific molecule 2 (ECSM2) have only recently begun to be understood. Limited
data suggest its involvement in cell migration and apoptosis. However, the underlying signaling mechanisms and novel
functions of ECSM2 remain to be explored.
Methodology/Principal Findings: A rabbit anti-ECSM2 monoclonal antibody (RabMAb) was generated and used to
characterize the endogenous ECSM2 protein. Immunoblotting, immunoprecipitation, deglycosylation, immunostaining and
confocal microscopy validated that endogenous ECSM2 is a plasma membrane glycoprotein preferentially expressed in
vascular endothelial cells (ECs). Expression patterns of heterologously expressed and endogenous ECSM2 identified that
ECSM2 was particularly concentrated at cell-cell contacts. Cell aggregation and transwell assays showed that ECSM2
promoted cell-cell adhesion and attenuated basic fibroblast growth factor (bFGF)-driven EC migration. Gain or loss of
function assays by overexpression or knockdown of ECSM2 in ECs demonstrated that ECSM2 modulated bFGF-directed EC
motility via the FGF receptor (FGFR)-extracellular regulated kinase (ERK)-focal adhesion kinase (FAK) pathway. The
counterbalance between FAK tyrosine phosphorylation (activation) and ERK-dependent serine phosphorylation of FAK was
critically involved. A model of how ECSM2 signals to impact bFGF/FGFR-driven EC migration was proposed.
Conclusions/Significance: ECSM2 is likely a novel EC junctional protein. It can promote cell-cell adhesion and inhibit bFGF-
mediated cell migration. Mechanistically, ECSM2 attenuates EC motility through the FGFR-ERK-FAK pathway. The findings
suggest that ECSM2 could be a key player in coordinating receptor tyrosine kinase (RTK)-, integrin-, and EC junctional
component-mediated signaling and may have important implications in disorders related to endothelial dysfunction and
impaired EC junction signaling.
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Introduction
Angiogenesis is not only essential for normal organ growth,
development and wound healing, but also an important
determinant for many diseases such as cancer, atherosclerosis,
diabetic retinopathies, and rheumatoid arthritis [1,2]. Endothelial
cells (ECs) that line the lumina of blood vessels are important
players in blood vessel formation, and directed EC migration is a
key component of the angiogenic process. Accordingly, there has
been a long-standing interest in identifying genes specifically or
preferentially expressed in ECs and understanding their biological
functions. This may lead to the discovery of new pathways and
molecular targets with therapeutic potentials. Endothelial cell-
specific molecule 2 (ECSM2) [3,4], also known as endothelial cell-
specific chemotaxis receptor (ECSCR) [5] and apoptosis regulator
through modulating cIAP expression (ARIA) [6], was initially
identified a decade ago by in silico cloning of novel EC-specific
genes [7]. Although human ECSM2 was predicted to encode a
hypothetical protein with a suggested role in cell adhesion based
on its putative amino acid profile [7], its biological and cellular
functions have only recently begun to be understood.
We and others have independently demonstrated that a family
of evolutionarily conserved ECSM2 genes from a variety of species
is preferentially expressed in ECs and vasculature [3,4,5,6]. These
studies also suggest that ECSM2 is involved in cell migration,
angiogenesis and apoptosis albeit some of the results are
controversial [8]. The effects of ECSM2 on cell migration could
be related to actin remodeling [3,4] via crosstalk with receptor
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(EGFR) [3] and vascular endothelial growth factor receptor
(VEGFR) [5]. ECSM2 is emerging as a promising therapeutic
target due to its endothelial specificity and potential roles in EC
migration and apoptosis [8]. However, novel functions of ECSM2
and its signaling mechanisms remain to be elucidated, which are
primary goals of the present study.
Among numerous growth factors that have been implicated in
angiogenesis and vascular remodeling, basic fibroblast growth
factor (bFGF) is a potent angiogenic inducer that can stimulate EC
migration and proliferation via interaction with its specific
receptor FGFR, a member of the RTK superfamily
[9,10,11,12]. In this study, we focus on the impact of ECSM2
on bFGF/FGFR actions in ECs. Using multiple experimental
approaches, we provide strong evidence suggesting that ECSM2 is
an EC junctional protein and promotes cell-cell adhesion. We
further demonstrate that ECSM2 can inhibit bFGF-driven cell
motility via the extracellular regulated kinase (ERK)-focal
adhesion kinase (FAK) pathway. Finally, we provide a model of
how ECSM2 contributes to the regulation of EC migration. Our
novel findings suggest that ECSM2 could be a key player in
coordinating RTK-, integrin-, and EC junctional component-
mediated signaling. Given the importance of RTK, adhesion and
junction signaling, the current work also lays a foundation for
future studies of more detailed roles of ECSM2 within the
signaling network of ECs.
Results
Generation of anti-ECSM2 monoclonal antibody and
characterization of endogenous ECSM2
We and others have recently demonstrated that the ECSM2
gene is preferentially expressed in vascular ECs largely by means
of quantitative RT-PCR and in situ hybridization [3,4]. Bioinfor-
matics analysis and heterologous expression of GFP-, myc-, or
FLAG-tagged ECSM2 proteins in several mammalian cell systems
further suggested that ECSM2 is a cell membrane protein
consisting of an N-terminal extracellular domain (ECD), a single
transmembrane domain (TM), and a small, highly conserved C-
terminal intracellular domain (ICD) [3,4,6]. To study the
endogenous ECSM2 protein, here we generated rabbit anti-
ECSM2 monoclonal antibodies (RabMAb) using a GST fusion
protein containing the entire ICD of human ECSM2 as the
immunogen (Figure 1). One hybridoma subclone (RabMAb 71-1)
specifically detected the endogenous ECSM2 proteins in human
EC lines (HUVEC and HDMVEC) by immunoblotting
(Figure 1D). The appearance of diffuse, multiple bands on SDS-
PAGE (50–60 kDa, significantly larger than the predicted
molecular mass of 25–30 kDa) could be due to some posttrans-
lational modifications such as glycosylation. Notably, this Rab-
MAb subclone can hardly detect the ECSM2 in mouse endothelial
MS1 cells (Figure 1D) although quantitative RT-PCR revealed the
presence of ECSM2 mRNA in MS1 (Figure 1E). However, its
mRNA level in MS1 cells was only 3.862.2% of that in HUVEC
when normalized to GAPDH (Figure 1E). This indicated that the
endogenous ECSM2 level was indeed low in MS1 cells, making it
an appealing system to investigate the cellular functions of ECSM2
in ECs by overexpression (see below). In addition, the cell
membrane localization of endogenous ECSM2 in HUVEC can be
detected by immunostaining with this RabMAb and confocal
microscopy (Figure 1F), which confirmed the previous findings of
heterologously expressed tagged ECSM2 proteins [3,4,6].
It has been hypothesized that ECSM2 is a heavily glycosylated
protein based on at least two facts. First, there are several
conserved N- and O-linked glycosylation sites in the extracellular
domain of ECSM2 proteins across species. Second, the size of
heterologously expressed ECSM2 protein is nearly twice of
predicted molecular mass from the amino acid sequences [3,4,6]
(also see Figure 1D for endogenous ECSM2). For many
glycoproteins, the particular patterns of glycosylation dictate
specific alterations in their migration on SDS-PAGE as
demonstrated previously [13]. Thus, we performed enzymatic
deglycosylation experiments to test whether the difference
between the actual and predicted sizes of ECSM2 was related
to glycosylation (Figure 2). We first enriched the ECSM2 protein
from total cell lysates of HUVEC by immunoprecipitation (IP)
with anti-ECSM2 RabMAb and then treated it with a mixture of
glycosidases to remove both N-a n dO-glycans under denaturing
conditions. As shown in Figure 2A, after resolved by SDS-PAGE
and immunoblotted with anti-ECSM2, the majority of precip-
itated proteins migrated much more rapidly upon deglycosyla-
tion, changing from 50–60 kDa to ,30 kDa (Figure 2A, lane
3 vs. 2). Notably, however, there remained some fractions with
molecular mass of 50–60 kDa in the glycosidase-treated sample
(Figure 2A, lane 3), suggesting that other mechanisms may
contribute to the retardation of ECSM2 migration on SDS-
PAGE in this cell context (see Discussion). To corroborate the
finding of glycosylation, we performed non-IP-based deglycosyla-
tion assays using HEK293 cells overexpressing ECSM2-FLAG
(Figure 2B). A nearly complete downshift of ECSM2-FLAG
migration (from ,40 kDa to ,30 kDa) on SDS-PAGE was
revealed by immunoblotting with both anti-FLAG and anti-
ECSM2 (Figure 2B, lane 2 vs. 1, lane 4 vs. 3), indicating that
ECSM2-FLAG also undergoes glycosylation. In addition, we
noted the difference in molecular mass of endogenous, mature
ECSM2 in HUVEC (50–60 kDa) versus heterologously ex-
pressed, mature ECSM2-FLAG (,40 kDa) in HEK293 cells (see
Discussion).
Identification of ECSM2 as a novel cell-cell junctional
protein
We have previously examined the impact of ECSM2 on EGF-
directed cell migration by coexpression of ECSM2-GFP and
EGFR in a non-EC cell line, HEK293 [3]. Here we sought to
further explore novel ECSM2 functions and signaling mechanisms
underlying its effects on cell motility in a more physiologically
relevant endothelial system. As endogenous ECSM2 expression is
low in MS1 cells (Figure 1D and 1E), we established the MS1 cells
stably overexpressing ECSM2-GFP (referred to as MS1/ECSM2-
GFP) or GFP alone (referred to as MS1/GFP). As expected,
ECSM2-GFP appeared highly glycosylated with a much larger
molecular mass than predicted (,75 versus ,50 kDa) (Figure
S1A) and was localized to the cell membrane (Figure S1B). As we
previously reported for MS1 transient transfectants [3], the
filopodia-like structures were evident in the MS/ECSM2-GFP
stable cell line when cell density was low (Figure S1B, arrowheads).
Surprisingly, when cells reached a high density, we observed
significantly enhanced cell-cell junctional localization of ECSM2-
GFP (Figure S1C, arrows). Similar patterns were also detected in
HEK293 cells overexpressing ECSM2 tagged with either GFP or
FLAG (Figure S1D).
b-catenin, a well-acknowledged component of the cadherin-
catenin complex constituting adherens junctions [14,15], has been
successfully utilized as a cell-cell junctional marker in our previous
study [16]. We thus immunostained the MS1/ECSM2-GFP cells
with an anti-b-catenin antibody. The results indicated that
ECSM2-GFP was markedly colocalized with b-catenin
(Figure 3A). We further performed confocal microscopy and
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confirmed that ECSM2 and b-catenin were indeed mainly
colocalized at cell-cell junctions (Figure 3B). In contrast,
ECSM2-GFP did not localize to focal adhesions (FAs) where
abundant FAK (a marker of FAs [16,17]) was detected (Figure S2).
Similarly, we also examined the subcellular distribution of
endogenous ECSM2 in HUVEC by coimmunostaining with
anti-ECSM2 RabMAb and anti-b-catenin, in which a non-EC
human cell line DU145 was used as a control for anti-ECSM2
RabMAb (Figure 4A). Both standard fluorescent microscopy
(Figure 4A) and confocal microscopy including Z-sectioning
(Figure 4B) identified the overlapping distributions of ECSM2
and b-catenin in HUVEC. Notably, unlike the b-catenin staining
(seen as a sharp, more defined belt along the cell contact area in
general), the distribution of ECSM2 in HUVEC appeared to be
rather less focused, although they did extensively overlap (Figure 4).
This finding may reflect the molecular diversity and complexity of
cell adhesions in ECs (see Discussion).
ECSM2 promotes cell-cell adhesion and inhibits bFGF-
directed cell migration
The prominent localization of ECSM2 to intercellular junctions
prompted us to investigate its potential roles in cell-cell adhesion
and cell motility, two related cellular processes essential for many
key endothelial functions. We performed cell aggregation assays in
both HEK293 and MS1 cell systems. In the representative
experiment using HEK293 cells stably overexpressing GFP,
human and mouse ECSM2-GFP, respectively, shown in
Figure 5A, large cell-cell aggregates were seen in the cells
expressing ECSM2-GFP but not in those only expressing GFP.
A total of approximately 1,000 cells were counted under each
condition for both HEK293 and MS1 cell systems and the
aggregation indexes were calculated. As displayed in Figure 5B
and 5C, forced expression of ECSM2-GFP in both HEK293 and
MS1 cells significantly promoted cell-cell adhesion when com-
pared to the GFP control (P,0.01).
Figure 1. Generation of rabbit anti-ECSM2 monoclonal antibody (RabMAb) and characterization of endogenous ECSM2. (A) Diagram
of human ECSM2 constructs used in generation and screening of anti-ECSM2 antibodies. SP, signal peptide; TM, transmembrane domain; ECD,
extracellular domain; ICD, intracellular domain. (B) Anti-ECSM2 antiserum specifically detects His-ICD. Purified GST-ICD proteins were used to
immunize the rabbit to generate polyclonal antibody (pAb) and monoclonal antibody (RabMAb) sequentially as detailed in Methods. Antiserum
(bleed containing pAb) was collected and used for immunoblotting. His-Ctrl: His-tagged non-related protein (control). (C) Anti-ECSM2 pAb recognizes
ECSM2-GFP but not GFP. Protein extracts from the HEK293 cells overexpressing human ECSM2-GFP or GFP alone were used for immunoblotting. (D)
Anti-ECSM2 RabMAb specifically detects endogenous ECSM2 in human ECs. Protein extracts from human EC lines (HUVEC and HDMVEC), mouse
endothelial MS1 cells, and non-EC lines (MCF-7, DU145 and HEK293) were analyzed by immunoblotting with anti-ECSM2 RabMAb subclone 71-1
(hybridoma supernatant) or anti-b-actin (loading control). (E) Quantitative RT-PCR analysis measuring the ECSM2 mRNA levels in HUVEC and MS1
cells, normalized to human and mouse GAPDH, respectively. Data are mean6SEM (n=6). **, P,0.01. (F) Plasma membrane localization of
endogenous ECSM2. HUVEC was costained with anti-ECSM2 RabMAb (subclone 71-1) (red) and DAPI (blue), and visualized by confocal microscopy.
Human prostate cancer DU145 cells were used as a negative control for anti-ECSM2. Scale bar, 20 mm.
doi:10.1371/journal.pone.0021482.g001
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GFP in HEK293/EGFR cells (constitutively expressing EGFR)
inhibits the EGF-induced cell migration [3]. Here we sought to
investigatethe effectsofECSM2onbFGF/FGFR-drivenmotilityin
ECs, given that bFGF has been considered as an angiogenic factor
and bFGF/FGFR signaling plays an important role in vascular
development and EC functions including migration [10,12]. Since
MS1 and HUVEC cells are highly responsive to bFGF, reflected in
bFGF-induced robust ERK activation [18] (Figure S3), we assessed
bFGF-directed EC migration by transwell assays. The results
indicated that overexpression of ECSM-GFP in MS1 cells
significantly attenuated bFGF-induced motility (Figure 6A).
As an alternative approach, we performed siRNA knockdown
experiments. Transfection of ECSM2 siRNA, but not nonspecific
(NS) control siRNA, into HUVEC significantly reduced the
ECSM2 expression at both mRNA and protein levels (Figure 6B).
Importantly, the immunoblotting results (Figure 6B, left panel)
further confirmed the specificity of our anti-ECSM2 RabMAb. In
contrast to the effects on cell motility by overexpression of
ECSM2-GFP in MS1 cells, knockdown of ECSM2 (ECSM2-KD)
in HUVEC significantly enhanced the bFGF-induced cell
migration (Figure 6C). Taken together, our data demonstrate that
ECSM2 is likely a previously unappreciated intercellular junction
protein, promotes cell-cell adhesion, and inhibits bFGF-directed
cell migration.
Signaling mechanism underlying the effect of ECSM2 on
bFGF-driven cell migration
We further probed the signaling mechanism underlying the
effect of ECSM2 on cell motility. As mentioned above, bFGF
caused robust ERK activation in both MS1 and HUVEC cells
(Figure S3). Here we assessed the bFGF-elicited signaling in the
ECSM2 overexpression system. Interestingly, overexpression of
ECSM2-GFP in MS1 cells enhanced bFGF-induced ERK
activation compared to the GFP control (Figure 7A, upper panel,
lane 4 vs. 2). ERK has been implicated in the motility of numerous
cell types stimulated by growth factors including VEGF, FGF,
EGF, platelet-derived growth factor (PDGF), and insulin, which
involves phosphorylation of FAK [19,20]. Surprisingly, overex-
pression of ECSM2 inhibited bFGF-mediated FAK phosphoryla-
tion at Tyr397, the major autophosphorylation site [21,22]
(Figure 7B, upper panel, lane 4 vs. 2). Similar results were obtained
for phosphorylation at Tyr576 and Tyr577 sites (Figure S4), which
is required for FAK maximal activation [23]. The diminished
FAK activation upon ECSM2 overexpression was in agreement
with reduced motility in these cells (Figure 6A).
In addition to tyrosine phosphorylation, FAK can be phos-
phorylated at several serine residues including Ser910 in response
to a variety of stimuli, and this requires ERK activation [20,24].
Thus, we examined whether the reduced pFAK(Y397) level was
related to enhanced pFAK(S910) (presumably by pERKs) in our
cell system. Indeed, an elevated pFAK(Ser910) level (bFGF-
induced) was detected in MS1/ECSM2-GFP cells (Figure 7B,
middle panel, lane 4 vs. 2). Taken together, the pERK level
displayed a positive and negative relationship with pFAK(S910)
and pFAK(Y397) levels, respectively (Figure 7C–E).
We also evaluated the signaling profiles in the HUVEC system
where endogenous ECSM2 was knocked down by RNA
interference (Figure 6B). ECSM2-KD significantly inhibited
bFGF-induced ERK activation (Figure 8A and 8B) but enhanced
pFAK(Y397) under the basal condition (Figure 8A and 8C). In
contrast, we did not detect an apparent difference in pFAK(S910)
levels between the NS control and ECSM2-KD cells (Figure 8A;
Statistical analysis of pFAK(S910) can be found in Figure S5).
Interpretations of the interrelationships among pERK,
pFAK(S910) and pFAK(Y397) in the cases of ECSM2 overex-
pression and knockdown using our model are further discussed
below (see Discussion). Collectively, our novel findings suggest that
FAK can be an important effector in the ECSM2-regulated
migratory pathway in response to bFGF, although ECSM2 seems
to be an intercellular junction protein (Figures 3, 4, 5) and absent
at FAs (Figure S2).
ERK resides upstream of FAK in the ECSM2-regulated
migratory pathway
Previous studies have suggested a complicated relationship
between ERK and FAK in cell migration [19]. To test whether
Figure 2. Characterization of ECSM2 proteins by enzymatic
deglycosylation. (A) Glycosylation of endogenous ECSM2. HUVEC
lysates were immunoprecipitated with anti-ECSM2 RabMAb (lanes 2
and 3) or rabbit IgG as a control (lane 1). Samples were treated with (+)
or without (-) glycosidase mix, as detailed in Methods, resolved by SDS-
PAGE, and immunoblotted with anti-ECSM2 RabMAb. Positions of
glycosylated (mature) ECSM2, deglycosylated ECSM2, and IgG are
indicated. (B) Glycosylation of ECSM2-FLAG. HEK293 cells stably
expressing mouse ECSM2-FLAG were lysed and cell lysates were
directly subjected to enzymatic deglycosylation reactions as described
in Methods. Samples were analyzed by immunoblotting with anti-FLAG
M2 mAb (lanes 1 and 2) and anti-ECSM2 RabMAb (lanes 3 and 4),
respectively. Positions of glycosylated (mature) ECSM2-FLAG, and
deglycosylated ECSM2-FLAG are indicated.
doi:10.1371/journal.pone.0021482.g002
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regulated signaling cascades, we employed PD98059, a specific
pharmacological inhibitor of MEK1 (the upstream kinase of
ERKs), to block ERK activation [25,26,27], and then assessed
FAK phosphorylation. As expected, PD98059 inhibited bFGF-
induced ERK activation in both MS1/GFP and MS1/ECSM2-
GFP cells (Figure 9A, upper panel). In the absence of PD98059,
overexpression of ECSM2-GFP led to upregulation of bFGF-
induced pFAK(S910) (pFAK(S910) panel in Figure 9A, and
Figure 9B) and downregulation of bFGF-induced pFAK(Y397)
(pFAK(Y397) panel in Figure 9A, and Figure 9C), as already
observed (Figure 7). Notably, however, PD98059 treatment
abolished the difference of bFGF-induced pFAK(S910) levels
between MS1/GFP and MS1/ECSM2-GFP cells (Figure 9B).
Interestingly, the drug also eliminated the difference of bFGF-
induced pFAK(Y397) between the two cell lines (Figure 9C).
We further assessed bFGF-driven migration of MS1/GFP and
MS1/ECSM2-GFP cells in the presence or absence of PD98059
by transwell assays (Figure 9D). As previously shown in Figure 6A,
without PD98059 treatment, overexpression of ECSM2-GFP
significantly reduced bFGF-directed motility compared to the
GFP control (P,0.01) (Figure 9D). In contrast, inhibition of the
MEK/ERK pathway by PD98059 abrogated the difference of
bFGF-induced motility between MS1/GFP and MS1/ECSM2-
GFP cells (Figure 9D). Meanwhile, we noted that PD98059 also
reduced bFGF-directed migration in MS1/GFP cells (Figure 9D).
This is not surprising as several previous studies have demonstrat-
ed that blockade of ERK signaling attenuates cell migration
induced by growth factors such as VEGF and bFGF [28,29,30,31]
and the Ras/Raf/MEK/ERK cascade is an essential effector
required for most RTK function [32]. Taken together, we
conclude that ERK resides upstream of FAK within the
ECSM2-regulated migratory pathway in this cell context.
Discussion
Experimental validation of ECSM2 as an endothelial specific
protein and recent findings of its involvement in cell migration,
angiogenesis, and apoptosis [3,4,5,6] provide an exciting new
opportunity to exploit the signaling network behind, to acquire a
Figure 3. Colocalization of ECSM2-GFP with b-catenin. (A) Colocalization of ECSM2-GFP with b-catenin revealed by standard fluorescent
microscopy. MS1 cells expressing GFP (control) or ECSM2-GFP were costained with anti-b-catenin antibody and DAPI. Merged images of GFP (green),
b-catenin (red), and DAPI (blue) staining are shown. Scale bar, 20 mm. (B) Colocalization of ECSM2-GFP with b-catenin confirmed by confocal
microscopy. Z-sections of a representative image are also shown as merged results of GFP (green), b-catenin (red), and DAPI (blue). Scale bar, 20 mm.
doi:10.1371/journal.pone.0021482.g003
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network, and to study endothelial function/dysfunction related to
this important, new molecule. To this end, by employing multiple
approaches in the current study, we demonstrate that, being a
plasma membrane protein, ECSM2 is concentrated at cell-cell
contacts and promotes cell aggregation, suggesting that it is most
likely a novel EC junction component. Importantly, we define that
ECSM2 attenuates bFGF-mediated cell migration through the
FGFR-ERK-FAK pathway.
Previous studies using RT-PCR, Northern blotting, in situ
hybridization, bioinformatics analysis, and ectopic expression of
tagged ECSM2 proteins have suggested that ECSM2 is a heavily
glycosylated,cell plasmamembrane protein preferentially expressed
in vascular ECs [3,4,6]. In this study, we successfully generated a
rabbit anti-ECSM2 monoclonal antibody (RabMAb). Using this
RabMAb combined with immunoblotting, immunoprecipitation,
enzymatic deglycosylation, immunostaining, and confocal micros-
copy, we have experimentally validated the endogenous character-
istics of ECSM2. In particular, we have demonstrated that both
endogenous and tagged ECSM2 can undergo glycosylation in cells.
However, we note that the molecular mass of glycosylated ECSM2-
FLAG overexpressed in HEK293 cells was approximately 10–
20 kDa smaller than that of the endogenous mature ECSM2 in
HUVEC (Figure 2). This may reflect the nature of the glycosylation
process within the two different cell systems and/or incomplete
glycosylation for constitutively overexpressed proteins. We also note
that some mature ECSM2proteins inHUVECdid not downshiftto
the deglycosylated form on SDS-PAGE after enzymatic deglycosy-
lation. Although the glycosidase mix used includes all common
enzymes (see Methods for details) for removal of almost all N-linked,
all simple core 1 and core 3 O-linked, and certain long chain O-
linked glycans, we can not rule out the possibility that Endoglyco-
sidase H and additional exoglycosidases may be needed to release
otherwise resistant sugars from ECSM2. The other possibility is that
posttranslational modifications in addition to glycosylation (e.g.
ubiquitination) could be involved since a role of ECSM2 in
modulation of protein proteasomal degradation was previously
reported [6].
Figure 4. Endogenous ECSM2 also localizes to cell-cell junctions. (A) Colocalization of endogenous ECSM2 with b-catenin revealed by
standard fluorescent microscopy. HUVEC or DU145 (control) cells were costained with anti-ECSM2 RabMAb (subclone 71-1), anti-b-catenin, and DAPI.
Merged images of b-catenin (green), ECSM2 (red), and DAPI (blue) staining are shown. Overlapping distribution of endogenous ECSM2 and b-catenin
in HUVEC is indicated by arrows. Scale bar, 20 mm. (B) Colocalization of endogenous ECSM2 with b-catenin in HUVEC, confirmed by confocal
microscopy. Z-sections of a representative image are also shown as merged results of b-catenin (green), ECSM2 (red), and DAPI (blue). Scale bar,
20 mm.
doi:10.1371/journal.pone.0021482.g004
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the concentrated distribution of ECSM2 at cell-cell contacts. Our
data of enhanced homophilic cell-cell interactions by ECSM2
overexpression in both HEK293 and MS1 cells highly support that
ECSM2 is most likely a previously unappreciated EC junctional
protein. As a cell adhesion molecule (CAM), ECSM2 does not
belong to any of the known CAM superfamilies including
integrins, cadherins, immunoglobulins (IgSF), and selectins
[33,34], based on their primary sequence/structure comparison
(data not shown). Endothelial cell-cell junctions are specialized
membrane domains that not only maintain the integrity of
endothelium, but also play critical roles in cell-cell communica-
tions and vascular permeability [35]. Similar to epithelial cells,
ECs have two major types of junctions, namely adherens junctions
(AJ) and tight junctions (TJ). However, the endothelial junction
architecture is less defined and AJ and TJ are often intermingled,
whereas epithelial junctions are better organized with TJ localizing
apical to AJ [35]. The finding that both heterologously expressed
and endogenous ECSM2 proteins were largely colocalized with b-
catenin (an AJ component) at cell-cell contact areas, which was
confirmed by confocal microscopy and Z-sectioning, implies that
ECSM2 has a close relationship with AJ. However, the ECSM2
distribution along the cell junction appeared to not completely
overlap with the pattern of b-catenin in HUVEC. This raises the
possibility that ECSM2 might belong to a non-AJ junction type. It
is known that multiple adhesion systems may coexist in the same
cell [35,36]. Conceptually, different CAMs could coassemble into
the same junction type, exhibiting an extensive distribution
overlap. Alternatively, each adhesion system could develop
separately and the components might exhibit a mutually exclusive
distribution. Importantly, the junctions are dynamic and specific
relationships might change in response to a variety of stimuli [37].
Interestingly, an earlier study reported that platelet endothelial
adhesion molecule-1 (PECAM-1 or CD31), a member of the IgSF
superfamily, localizes at EC junctions but is not associated with
either AJ or TJ [36]. This finding along with ours provides an
additional line of evidence to the diversity and complexity of EC
junctions. Thus, the exact spatial, temporal and functional
interrelationships of ECSM2-mediated EC junctions to AJ, TJ,
or PECAM-1-associated junctions and definition of critical
domains responsible for homophilic cell-cell adhesion deserve
more detailed investigation in order to gain greater insight into
ECSM2 signaling.
Cell migration is a highly orchestrated process of leading-edge
protrusion, turnover of FAs, generation of tractional forces, and
rear retraction, which involves precise regulation of cell-cell
adhesion and cell-extracellular matrix (ECM) interaction [38].
The current discovery of junctional localization of ECSM2 and
our previous findings of inhibitory effects of ECSM2 overexpres-
sion on EGF/EGFR-driven migration in a non-EC cell line [3],
Figure 5. Overexpression of ECSM2 promotes cell aggregation. (A) HEK293 cells stably expressing GFP (control), human (h) or mouse (m)
ECSM2-GFP were used for cell aggregation assays, as described in Methods. Representative images captured by an inverted phase contrast
microscope (magnification: 610) are shown. Scale bar, 200 mm. (B and C) The aggregation indexes for HEK293 stably expressing GFP, human (h) or
mouse (m) ECSM2-GFP (B), and MS1 stably expressing GFP or human ECSM2-GFP (C) were calculated and plotted. Data are mean6SEM (n=8).
**, P,0.01.
doi:10.1371/journal.pone.0021482.g005
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EC migration and the underlying signaling mechanisms given the
important roles of bFGF in vascular development and EC
functions including migration [9,10,11,12]. We found that, while
promoting cell-cell adhesion, ECSM2 inhibited the bFGF-directed
cell migration using ‘‘gain or loss of function’’ assays by
overexpression or knockdown of ECSM2 in ECs. We further
defined that ECSM2 modulates bFGF-directed motility via the
FGFR-ERK-FAK pathway. In MS1 and HUVEC cells, either
overexpression or knockdown of ECSM2 altered bFGF-induced
ERK activation. Concomitantly, serine and tyrosine phosphory-
lation levels of FAK changed and exhibited positive and negative
relationships with pERK, respectively. FAK is a crucial signaling
component that regulates cell motility through influencing the
cytoskeleton, structures of cell adhesion sites and membrane
protrusions in response to a variety of stimuli [39]. Growth factor-
induced pERK-dependent pFAK(S910), its relationship to de-
phosphorylation of FAK at Tyr397, and its role in tumor
metastasis have been documented in several non-EC systems
[20,24,40,41]. Our additional new data in ECs presented in this
study point to an intriguing mechanism that serine phosphoryla-
tion of FAK could serve as a ‘‘brake’’ on its tyrosine
phosphorylation (activation) under certain circumstances. This is
reminiscent of the situation of EGFR that we have been
Figure 6. Effects of ECSM2 on bFGF-directed cell migration. (A) Overexpression of ECSM2-GFP attenuates bFGF-induced cell motility
measured by transwell assays. MS1 cells expressing GFP or ECSM2-GFP were allowed to migrate across the membrane of the transwell insert in
response to bFGF (10 ng/ml) in serum-free media for 5 h. The number of migrated cells per imaging field for each condition was counted. Data are
mean6SEM (n=12). **, P,0.01. (B) Knockdown of endogenous ECSM2 in HUVEC. HUVECs were transfected with ECSM2 siRNAs (sequence no. 146 or
147) or nonspecific (NS) siRNA. Total RNAs and proteins were extracted from the cells 48 and 72 h post-transfection, respectively, and used for
quantitative PCR and immunoblotting analyses. Statistical results of three independent experiments are shown. Data are mean6SEM. *, P,0.05. (C)
Knockdown of ECSM2 enhances bFGF-induced cell migration. HUVECs were transfected with nonspecific or ECSM2 siRNAs (sequence no. 146 or 147)
for 72 h and used for transwell assays. The cells were allowed to migrate in response to bFGF (10 ng/ml) in serum-free and ECGS-free media for 5 h.
The number of migrated cells per imaging field for each condition was counted. Data are mean6SEM (n=12). **, P,0.01.
doi:10.1371/journal.pone.0021482.g006
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ylation counterbalances its tyrosine phosphorylation [25,26,27]. In
this regard, activation of ERK signaling and a balance between
FAK tyrosine phosphorylation (activation) and pERK-dependent
serine phosphorylation of FAK are perhaps the prerequisites for
ECSM2 to exert its effects on bFGF-directed EC migration (see
model below). Indeed, pharmacological inhibition of the ERK
pathway eliminated the differences of bFGF-induced pFAK(S910),
Figure 7. Overexpression of ECSM2 affects bFGF-induced ERK and FAK signaling. (A and B) Serum-starved MS1 cells expressing GFP or
ECSM2-GFP were stimulated with vehicle (-) or bFGF (10 ng/ml) for 15 min. Protein extracts were analyzed by immunoblotting with anti-pERK, anti-
total ERK, anti-b-actin, anti-pFAK(Y397), anti-pFAK(S910), or anti-total FAK, as indicated. (C–E) Statistical analysis (densitometry) of pooled data of
pERK, pFAK(Y397), and pFAK(S910) from four independent experiments. Data are mean6SEM. *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0021482.g007
Figure 8. The effects of ECSM2 knockdown on bFGF-induced ERK and FAK signaling. (A) HUVECs were transfected with nonspecific (NS)
or ECSM2 siRNAs for 72 h, starved for 8 h, and then stimulated with vehicle (-) or bFGF (10 ng/ml) for 15 min. Protein extracts were analyzed by
immunoblotting with anti-pERK, anti-total ERK, anti-b-actin, anti-pFAK(Y397), anti-pFAK(S910), or anti-total FAK, as indicated. (B and C) Statistical
analysis of pooled data of pERK and pFAK(Y397) from three independent experiments. Data are mean6SEM. *, P,0.05.
doi:10.1371/journal.pone.0021482.g008
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MS1/GFP cells (Figure 9).
RTKs and CAMs are the cell-surface proteins that each can
sense the surrounding environment and influence the cell
behavior. It is now more believed that a tight relationship exists
between RTKs and CAMs, and that they can work together
through multiple mechanisms [42]. Based on our experimental
data, we propose a working model (Figure 10). Under normal
conditions (Figure 10A), ECSM2 can crosstalk with FGFR
(perhaps other RTKs) to activate ERKs, which causes FAK
phosphorylation at Ser910 to reach a balance between serine and
tyrosine phosphorylation (activation) of FAK (the latter could be
pre-activated by cell-ECM interaction through integrin signaling
[43]). When ECSM2 is overexpressed (Figure 10B), cell-cell
contacts and the ECSM2-FGFR crosstalk are enhanced, resulting
in elevated ERK activation, increased pFAK(S910) and decreased
pFAK(Y397) levels – pressing the ‘‘brake’’. Thus, bFGF-mediated
cell migration is inhibited. In contrast, loss of ECSM2 renders
FGFR to signal independently of ECSM2, in turn leading to
reduced ERK activation and decreased (at least not increased)
pFAK(S910). In this case, due to the release of the ‘‘brake’’ and
subsequent upregulation of pFAK(Y397), cell motility increases
(Figure 10C). Our additional pFAK and pERK data upon EC
attachment to fibronectin revealed an inverse relationship between
FAK tyrosine phosphorylation (upregulation) and ERK activation
(downregulation) (Figure S6), further supporting the idea that
alteration in pERK levels can modulate FAK activation via
pFAK(S910). This is similar to the case of ECSM2 knockdown
(Figure 8), in which downregulated pERK loses its influence over
pFAK(S910). Thus, pFAK(S910) remains at the basal level and
pFAK(Y397) increases accordingly (no ‘‘brake’’). Taken together,
our results clearly establish a critical role of ECSM2 in bFGF/
FGFR-driven cell motility and also imply its connection to integrin
signaling through the RTK (FGFR)-ERK-FAK pathway. This
undoubtedly introduces a new dimension to controlling the RTK
and/or integrin signaling.
We note that the limited literature on ECSM2 has already
shown some discrepancy, especially regarding its precise roles in
cell migration [3,4,6] (and this study) and its anti- or pro-
angiogenic effects [4,5,6]. As for the impact of ECSM2
knockdown in HUVEC on growth factor-mediated cell migration
per se, experimental data from us and three other groups [4,5,6]
are not consistent. This may have resulted from different assay
conditions and individual growth factors that have been used.
Armstrong et al. [4] used 20% serum plus 50 mg/ml endothelial
cell growth supplement (ECGS) (presumably the same as in full
growth medium for HUVEC) and Verma et al. [5] used 10%
serum or 25 ng/ml VEGF in endothelial basal medium,
respectively, as chemoattractants in their transwell assays. Under
these experimental conditions, ECSM2 knockdown in HUVEC
resulted in reduced migration. In contrast, we used 10 ng/ml
bFGF in serum-free and ECSG-free starvation medium and
detected enhanced motility in ECSM2 knockdown cells. Surpris-
ingly, Ikeda et al. did not observe any effect of ECSM2 knockdown
on cell migration when 50 ng/ml VEGF was used as a
chemoattractant without description of medium, serum and
ECGS [6]. It is known that both serum and ECGS contain a
variety of growth factors that are required for cell growth. Thus,
they could override a specific effect exerted by a particular factor,
which is supported by an early finding that ectopic expression of a
Figure 9. ERK resides upstream of FAK in ECSM2-regulated
FGFR-ERK-FAK pathway. (A) Blockade of ERK activation eliminates
the upregulation of pFAK(Y397) and the downregulation of pFAK(S910)
(bFGF-induced) in MS1 cells expressing ECSM2-GFP versus GFP control
cells. Serum-starved cells were pretreated with DMSO (control) or
PD98059 (50 mM) for 1 h prior to stimulation with vehicle (-) or bFGF
(10 ng/ml) for 15 min. Protein extracts were analyzed by immunoblot-
ting with anti-pERK, anti-total ERK, anti-pFAK(S910), anti-pFAK(Y397), or
anti-total FAK, as indicated. (B and C) Statistical analysis (densitometry)
of pooled data of pFAK(S910) and pFAK(Y397) from three independent
experiments. Data are mean6SEM. **, P,0.01; ns, not statistically
significant. (D) Effect of inhibition of ERK activity on bFGF-induced cell
migration. Serum-starved MS1 cells stably expressing GFP or ECSM2-
GFP were pretreated with DMSO (control) or PD98059 (50 mM) for 1 h
prior to transwell assays, as detailed in Methods. The cells were allowed
to migrate across the membrane of the transwell insert in response to
bFGF (10 ng/ml) in serum-free media for 5 h. The number of migrated
cells per imaging field for each condition was counted. Data are
mean6SEM (n=12). **, P,0.01; ns, not statistically significant.
doi:10.1371/journal.pone.0021482.g009
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cell migration only when cells were stimulated with EGF but not
with serum [44]. Moreover, although both bFGF and VEGF are
considered as potent angiogenic factors capable of inducing EC
proliferation, migration, and angiogenesis via interactions with
their respective receptors, a number of studies have suggested that
they can utilize different signaling pathways (e.g. distinct integrins
and upstream/downstream effectors of FAK) to mediate these
angiogenic activity [28,45,46,47,48,49]. This, at least in part,
explains why ECSM2 knockdown has differential roles in
modulating VEGF- and bFGF-directed migration. Given that
the existing literature on the impact of ECSM2 knockdown on
VEGF-stimulated EC proliferation, migration, and Matrigel-based
tube formation (in vitro angiogenesis) has been somewhat
controversial (pro-angiogenic versus anti-angiogenic) [4,5,6,8], a
better understanding of the precise roles of ECSM2 on individual
growth factor-mediated angiogenic processes is needed.
Finally, it is important to point out how ECSM2 crosstalks or
interacts with the RTKs remains a key question to be addressed,
although the impact of ECSM2 on RTK signaling elicited by EGF
[3], VEGF [5], and bFGF (this study) is obvious. This could be
rather complicated and may not be explained by a simple,
straightforward mechanism at this point given the current
controversial data on ECSM2 functions related to different growth
factors and RTKs as just described. A wealth of evidence [42],
stemming from the initial observations that bFGF can only
activate FGFRs in the presence of additional molecules [50,51],
has dramatically changed our perception of ligand-dependent
activation of RTKs. In fact, CAMs can act as coreceptors for
RTKs and the collaboration with CAMs contributes to broaden
the diversity of the responses that are achieved by the receptors
[42]. For example, localization of E-cadherin at cell-cell junctions
or overexpression of E-cadherin blocks the FGF-induced coendo-
cytosis of FGFR1 and E-cadherin, and thus attenuates FGF/
FGFR1 signaling to the MEK/ERK pathway in epithelial cells
[52]. In contrast, the association of N-cadherin with FGFR1
prevents internalization and downregulation of the receptor and
leads to a prolonged ERK signaling [53]. In ECs, VE-cadherin
(vascular endothelial cadherin, a unique endothelial AJ component
[54,55]) is associated with VEGFR2 and this association inhibits
VEGFR2 phosphorylation and downstream signaling including
the ERK pathway [56,57]. At first glance, these results appear to
contradict one another, but in turn mechanistically suggest that
the fine-tuning of RTK activation and signaling might be
dependent on the presence of specific CAMs (possibly associated
with the RTKs) and perhaps the cellular context as well [42].
Nevertheless, these studies could offer several potential mecha-
nisms underlying the crosstalk between ECSM2 and RTKs, which
are worthy of future investigation. However, unlike other known
CAMs, the lack of predicted functional domains within the
intracellular segment of ECSM2 [3,4] suggests that this could be a
new challenge.
In conclusion, the current study is to our knowledge the first
demonstration that ECSM2 is an EC junctional component. In
concert with its stimulatory role on cell-cell adhesion, ECSM2
attenuates bFGF/FGFR-driven cell migration mechanistically
through the ERK-FAK pathway. Our work provides new insights
into understanding the roles of ECSM2 in endothelial cell-cell
interaction and motility. Restricted expression of ECSM2 to ECs,
its concentrated distribution at cell-cell contacts, and close
connection with RTKs, b-catenin, ERKs, and FAK raise the
possibility that ECSM2 could be a key player in coordinating
RTK-, integrin-, and EC junctional component-mediated signal-
ing. Since EC junctions control many key endothelial functions
Figure 10. Model of how ECSM2 signals to impact bFGF/FGFR-
driven endothelial cell migration. The model is proposed based on
the experimental data presented in this study. (A) In ECs, ECSM2 is
concentrated at cell-cell contacts and can crosstalk with FGFR (possibly
other RTKs) through some unknown interactions (see text for detailed
discussion) to activate ERKs (pERK), which causes FAK serine
phosphorylation (pS910) to counterbalance FAK tyrosine phosphoryla-
tion or activation (pY397). (B) When ECSM2 is overexpressed, cell-cell
adhesion and the ECSM2-FGFR crosstalk are enhanced, resulting in
elevated pERK, increased pFAK(S910) and decreased pFAK(Y397) levels
– pressing the ‘‘brake’’. Thus, bFGF/FGFR-mediated cell migration is
inhibited. (C) Knockdown of ECSM2 renders FGFR to signal indepen-
dently of ECSM2, in turn leading to reduced pERK and decreased (at
least not increased) pFAK(S910). Due to the release of the ‘‘brake’’ and
subsequent upregulation of pFAK(Y397) – FAK activation, cell motility is
enhanced.
doi:10.1371/journal.pone.0021482.g010
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situations such as inflammation and angiogenesis [54,58], our
strategic findings also allow speculation that ECSM2 may play an
important role in regulation of vascular permeability and stability
in diseases. Undoubtedly, this will be an interesting area for future
studies.
Materials and Methods
Cells, antibodies and reagents
HEK293 cells and mouse endothelial MS1 cells (both from
ATCC, Manassas, VA) were grown in DMEM containing 10%
fetal bovine serum (FBS) (Mediatech, Manassas, VA). Human
umbilical vein endothelial cells (HUVEC) and human dermal
microvascular endothelial cells (HDMVEC) (both from Vec
Technologies, Rensselaer, NY) were maintained in MCDB-131
complete medium containing 10% FBS and 200 mg/L of
endothelial cell growth supplement (ECGS) (Vec Technologies).
Human prostate cancer DU145 and breast cancer MCF-7 cells
(both from ATCC) were grown in RPMI 1640 medium containing
10% FBS. All antibodies used are detailed in Table S1.
Recombinant human bFGF was purchased from Sigma (St. Louis,
MO) and the MEK inhibitor PD98059 was from Cell Signaling
(Beverly, MA).
RNA extraction, RT-PCR, and quantitative PCR
Total RNAs were extracted from tissue and cells using TRIzol
Reagent (Invitrogen, Carlsbad, CA). cDNA synthesis was
performed with SuperScript III First-strand Synthesis Supermix
(Invitrogen) and PCR was carried out using Pfu Ultra DNA
polymerase (Agilent Technologies, Santa Clara, CA). Quantitative
PCR was performed using Platinum SYBR Green qPCR Super-
mix UDG Kit (Invitrogen) on the iQ5 Real-Time PCR Detection
System (Bio-Rad, Hercules, CA). Expression of ECSM2 was
normalized to GAPDH.
Plasmid constructs, cell transfection, and generation of
stable cell lines
cDNAs encoding full-length human and mouse ECSM2,
respectively, were obtained by RT-PCR and cloned into
pEGFP-N1 (Clontech Laboratories, Palo Alto, CA) or
p36FLAG-CMV-14 (Sigma), as described previously [3,16].
Plasmid DNAs were transfected into HEK293 cells with
Lipofectamine 2000 (Invitrogen) and stable cell lines were
generated by selection with 1 mg/ml of G418 [3,16]. The MS1
cells stably expressing ECSM2-GFP or GFP alone were obtained
by cotransfection of respective expression construct with
pcDNA3.1-Hygro (Invitrogen) and selected with 0.2 mg/ml of
hygromycin.
Generation and screening of rabbit anti-ECSM2
monoclonal antibody (RabMAb)
The cDNA fragment encoding the entire intracellular domain
(ICD) of human ECSM2 was cloned into pGEX-4T-1 (GE
Healthcare, Piscataway, NJ) or pET-16b (EMD Chemicals,
Gibbstown, NJ). The two recombinant plasmids were used to
transform E. coli BL21(DE3)pLys strain and expression of
glutathione S-transferase (GST)-tagged or His-tagged ICD fusion
proteins in E. coli was induced with IPTG. The GST- and His-
fusion proteins were purified using glutathione-Agarose 4B (USB
Corporation, Cleveland, OH) and Ni-NTA Agarose (Qiagen,
Valencia, CA), respectively. The purified GST-ICD fusion
proteins were used as the antigen to generate rabbit monoclonal
antibody (RabMAb) using the custom antibody services provided
by Epitomics, Inc (Burlingame, CA). Briefly, two New Zealand
white rabbits were injected with GST-ICD proteins (0.2 mg
proteins per injection, 4–5 injections). Two test bleeds were
collected and used for primary screening sequentially by ELISA
against His and/or GST and by immunoblotting using purified
His-ICD proteins and total protein extracts from HEK293 cells
overexpressing ECSM2-GFP versus GFP control. To generate
hybridomas, isolated spleen cells from one immunized rabbit
(positive in antiserum screening) were fused with rabbit fusion
partner cells (plasmacytoma) [59]. Positive hybridoma clones were
identified by differential ELISA and further screened by
immunoblotting in a panel of cell lines including HEK293 cells
overexpressing ECSM2-GFP and endothelial cell lines endoge-
nously expressing ECSM2 (Figure 1).
Knockdown of ECSM2 in HUVEC cells
Predesigned siRNAs specifically targeting human ECSM2 gene
(Sequence no. 146: 59-GAGUUCAGGGCUGUCUGAA-39
(sense), 59-UUCAGACAGCCCUGAACUC-39 (antisense); Se-
quence no. 147: 59-CAUGAAUAAUGGCAAACAA-39 (sense),
59-UUGUUUGCCAUUAUUCAUG-39 (antisense)) and universal
negative (nonspecific) control siRNA were purchased from Sigma.
HUVECs were transfected with 200 nM of siRNA duplexes using
HiPerFect Transfection Reagent (Qiagen), as described previously
[26]. The transfectants were used for various assays 48–72 h post
transfection as specified in each experiment.
Immunofluorescent staining and microscopy
Cells were grown on glass coverslips precoated with gelatin (2%)
or fibronectin (20 mg/ml) and fixed in 4% paraformaldehyde for
15 min, permeabilized with 0.25% Triton X-100 in PBS
containing 1% BSA for 15 min, stained with mouse anti-FAK
mAb clone 4.47 (Millipore), rabbit anti-ECSM2 RabMAb 71-1
(hybridoma supernatant), and/or mouse anti-b-catenin mAb (BD
Biosciences) as specified in each experiment. The mouse and
rabbit antibodies were detected with FITC- or TRITC-conjugated
anti-mouse or anti-rabbit IgG antibody as specified in each
experiment. The coverslips were mounted onto microscope slides
in Vectashield mounting medium for fluorescence containing
DAPI (Vector Laboratories, Burlingame, CA) and fluorescent
images were visualized and captured using a Zeiss Axio Imager
upright fluorescent microscope and a Zeiss Laser Scanning
Confocal Microscope LSM 710 (Carl Zeiss USA, Thornwood,
NY), as described previously [3,16,26].
Cell aggregation assay
Cell aggregation assays were performed using a modified
protocol as described elsewhere [60]. Briefly, cells were washed
with PBS (without Ca
2+ and Mg
2+), trypsinized with 0.05%
trypsin containing 0.5 mM Ca
2+, and washed with HCMF buffer
(10 mM HEPES, pH 7.4, 137 mM NaCl, 5.4 mM KCl,
0.34 mM Na2HPO4?12H2O, and 0.1% glucose) to remove the
Ca
2+. The cells were resuspended at 10
5 per 0.5 ml in HCMF
containing 1 mM Ca
2+ in 1.5 ml tubes and rotated at 37uCf o r
30 min. The cells were then transferred to a 24-well plate and
shaken for additional 30 min. Images of 8 random areas per well
were captured using a Zeiss Axiovert 200 M inverted microscope
(Carl Zeiss USA) to observe cell aggregates. Approximately 1,000
cells were counted under each condition. The aggregation index
(Nt/N0) was calculated (Nt=total particle number, including
aggregates and single cells; N0=total cell number in cell
suspension).
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BD Falcon 8- mm pore inserts (BD Biosciences, San Diego, CA)
were placed in a 12-well plate containing 1 ml of starvation
medium with or without bFGF (10 ng/ml) (lower chamber).
Serum-starved cells were trypsinized and counted. Cell suspen-
sions in 0.5 ml of starvation medium were then added to the
transwell inserts (1610
5 cells per well) (upper chamber) and
incubated at 37uC for 5 h. In the case of PD98059 pretreatment,
serum-starved cells were pretreated with PD98059 (50 mM) for 1 h
prior to trypsinization and PD98059 (50 mM) was added to the
media in both lower and upper chambers. At the end of
incubation, the cells were fixed by submerging the transwell
inserts in 4% paraformaldehyde and counterstained with DAPI
(0.5 mg/ml). The non-migrated cells on the top side of the
membrane were removed with wet cotton swabs. Air dried
membranes were cut out from the transwell inserts, mounted onto
microscope slides, and examined using a Zeiss Axio Imager
upright fluorescent microscope (Carl Zeiss USA), as described
previously [26]. The cells from 12 randomly selected fields were
counted.
Cell starvation, inhibitor treatment, stimulation, protein
extraction, and immunoblotting
Cell starvation, drug pretreatment, stimulation, protein extrac-
tion, and immunoblotting (IB) were performed as previously
described [13,25,26,27]. Briefly, cells were starved in serum-free
(and ECGS-free, if applicable) medium containing 0.5% BSA for
5-16 h, pretreated with PD98059 (50 mM) or vehicle (DMSO) for
1 h, and then stimulated with bFGF (10 ng/ml) at 37uC for
15 min. The cells were harvested, lysed, and solubilized in Lysis
Buffer A (50 mM Tris-HCl (pH8.0), 2 mM EDTA, 150 mM
NaCl, 100 mM NaF, 10% glycerol, and 1% SDS) with protease
and phosphatase inhibitors. The cell extracts were quantitated
with bicinchoninic acid (BCA) reagents (Pierce, Rockford, IL) and
used for immunoblotting with antibodies as specified in each
experiment. Immunoblotting signals were detected with Super-
Signal chemiluminescent substrate (Pierce) and images were
captured using a Kodak 4000 MM molecular imager.
Immunoprecipitation and enzymatic deglycosylation
Enzymatic deglycosylation assays were performed using either
immunoprecipitated proteins or cell lysates. For HUVEC,
immunoprecipitation (IP) experiments were performed as we
described elsewhere [25,27]. Specifically, HUVEC cells were
lysed in Lysis Buffer B (50 mM Tris-HCl (pH 8.0), 2 mM EDTA,
150 mM NaCl, 100 mM NaF, 10% glycerol, and 1% Triton X-
100) with protease and phosphatase inhibitors. Cell extracts
(1.5 mg) were mixed with 150 ml of anti-ECSM2 RabMAb 71-1
(hybridoma supernatant) and incubated at 4uC overnight with
continuous agitation. Protein A-Sepharose beads (Amershan
Pharmacia Biotechnology, Arlington Heights, IL) were added
and incubated at 4uC for additional 2 h. The beads were washed
three times with Lysis Buffer B adjusted to 0.5% Triton X-100.
Precipitated proteins were eluted by boiling the beads in
16Glycoprotein Denaturing Buffer (0.5% SDS and 40 mM
DTT) for 10 min. Enzymatic deglycosylation reaction (total
volume of 50 ml) was accomplished by adjusting the buffer to
50 mM sodium phosphate (pH 7.5) and 1% Nonidet P-40 and
adding 5 ml of Deglycosylation Enzyme Mix consisting of
PNGase F, Endo-a-N-Acetylgalactosaminidase, Neuraminidase,
b1-4 Galactosidase, and b-N-Acetylglucosaminidase (New En-
gland BioLabs, Beverly, MA) and incubated at 37uCf o r4h ,
according to the manufacturer’s suggestions. Nondeglycosylated
controls were subjected to the same treatment, but without the
addition of the Deglycosylation Enzyme Mix, as previously
described [13].
For HEK293 cells stably expressing ECSM2-FLAG, cells were
lysed in RIPA buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl,
1% Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) with
protease and phosphatase inhibitors. Cell lysates (100 mg) were
denatured by boiling in 16Glycoprotein Denaturing Buffer (0.5%
SDS and 40 mM DTT) for 10 min and used directly in enzymatic
deglycosylation reactions as above. After glycosidase digestion,
SDS-PAGE sample buffer was added and incubated at 100uC for
5 min. The samples were analyzed by immunoblotting.
Densitometry and statistical analysis
Densitometric quantification of digital immunoblotting images
was performed using Kodak Molecular Imaging Software (Version
4.0) [3,26]. All statistical data were from multiple experiments or
measurements and presented as mean6SEM. The significance (p
value) of differences was estimated using unpaired Student’s t-test
and p,0.05 was considered significant.
Supporting Information
Figure S1 Initial identification of concentrated distri-
bution of ECSM2 at cell-cell contacts. (A and B) Generation
of MS1 cells stably expressing ECSM2-GFP or GFP alone, verified
by immunoblotting with anti-GFP (A) and by visualization of GFP
fluorescence (B). The filopodia-like structures (B) are indicated by
arrowheads. Scale bar, 20 mm. (C and D) Localization of ECSM2
(tagged with GFP or FLAG) at cell-cell junctions when
heterologously expressed in MS1 (C) and HEK293 (D) cells.
Merged images of GFP (green) or FLAG (red) with DAPI (blue) are
shown. Scale bar, 20 mm.
(TIF)
Figure S2 ECSM2 does not localize to focal adhesions
(FAs). MS1 cells expressing ECSM2-GFP were costained with
anti-FAK antibody and DAPI. ECSM2-GFP (green), FAK (red),
DAPI (blue) staining, and merged image are shown. Concentrated
distribution of ECSM2-GFP at cell-cell contacts are indicated by
arrows. Scale bar, 20 mm.
(TIF)
Figure S3 bFGF-induced ERK signaling is more robust
than VEGF in ECs. (A) Serum-starved MS1 cells were
stimulated with 10 ng/ml of VEGF or bFGF for 15 min. Protein
extracts were analyzed by immunoblotting with anti-pERK and
anti-total ERK antibodies, respectively. (B) HUVEC cells were
starved in the media free of serum and endothelial cell growth
supplements (ECGS) for 8 h, and then stimulated with 10, 25, and
50 ng/ml of VEGF or bFGF for 15 min. Protein extracts were
analyzed by immunoblotting with anti-pERK and anti-total ERK
antibodies, respectively.
(TIF)
Figure S4 ECSM2 overexpression attenuates bFGF-
induced FAK phosphorylation at Tyr576 and Tyr577.
(A) Serum-starved GFP- or ECSM2-GFP-overexpressing MS1
cells were stimulated with vehicle (-) or bFGF (10 ng/ml) for
15 min. Protein extracts were analyzed by immunoblotting with
anti-pFAK(Y576/Y577) and anti-total FAK, respectively. (B)
Statistical analysis (densitometry) of pooled data of pFAK(Y576/
Y577) from four independent experiments. Data are mean6SEM.
**, P,0.01.
(TIF)
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knockdown. HUVECs were transfected with nonspecific (NS) or
ECSM2 siRNAs for 72 h, starved for 8 h, and then stimulated
with vehicle (-) or bFGF (10 ng/ml) for 15 min. Protein extracts
were analyzed by immunoblotting with anti-pFAK(S910) as shown
in Fig. 9A. Statistical analysis (densitometry) of pooled data of
pFAK(S910) from three independent experiments did not show
statistical significance. Data are mean6SEM.
(TIF)
Figure S6 There exists a balance among ERK activation
and FAK tyrosine and serine phosphorylation upon cell
attachment to fibronectin. HUVECs were trypsinized,
resuspended in complete growth media, seeded in fibronectin-
precoated 35 mm dishes, and cell attachment was allowed for 0,
20, 40 and 60 min. Protein extracts were analyzed by immuno-
blotting with anti-pFAK(Y397), anti-pFAK(Y576/Y577), anti-
pFAK(S910), anti-total FAK, anti-pERK, anti-total ERK, or
anti-b-actin antibodies, as indicated.
(TIF)
Table S1 List of antibodies used in the study.
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